Avoro Capital Advisors LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001633313
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 30 positions · Total reported value $6.74B · Top-10 concentration 74.4% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 62.1% · 3 new · 15 cut · 0 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -15.9% · vs SPY -18.0% · Prev Value $11.14B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -0.4% · vs SPY -2.6% · Latest Value $9.67B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, Avoro Capital Advisors LLC disclosed 30 equity positions with a combined reported value of $6.74B. The filing implies a focused portfolio: its ten largest positions account for 74.4% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were ASND ($1.02B), MDGL ($840.72M), ARGX ($730.18M). By sector, the heaviest allocations are Health Care 71.8%, Other 28.2%. Versus the prior quarter, allocation shifted toward Other (+6.1pp) and away from Health Care (-6.1pp).
Versus the prior quarter, Avoro Capital Advisors LLC opened 3 new positions, trimmed 15 and fully exited 0, a turnover rate of 62.1% of positions. The portfolio's overlap with the prior quarter was 82% of names.
The largest new positions opened in Q3 2025 were ORKA ($25.64M), TNGX ($4.58M), GPCR ($2.24M).
Of the 3 positions fully exited versus the prior quarter, the largest were BPMC ($48.07M), GLUE ($16.80M), RARE ($12.00M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- ORKA ORUKA THERAPEUTICS INC · $25.64M
- TNGX TANGO THERAPEUTICS INC · $4.58M
- GPCR STRUCTURE THERAPEUTICS INC · $2.24M
Insider Transactions (Form 4)
Latest Avoro Capital Advisors LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-28 | Buy | Scribe Therapeutics, Inc. | 7,905 | $18.25 | SEC filing |
| 2026-07-24 | Buy | Scribe Therapeutics, Inc. | 50,000 | $22.31 | SEC filing |
| 2026-07-24 | Buy | Scribe Therapeutics, Inc. | 2,333,333 | $15.00 | SEC filing |
Fund Profile
Avoro Capital Advisors LLC is an SEC-registered 13F filer based in New York, NY, United States. As of Q2 2026 it reported 26 US equity positions with a combined value of $11.14B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: NEW YORK, NY, United States
- SEC registration: 801-74391 (status: Approved), registered 2012-03-30
- Regulatory AUM (Form ADV): $13.55B as of 2026-03-05
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 2 private funds, of which 1 hedge funds
- Website: avorocapital.com
Portfolio Structure
- 26 positions · $11.14B reported value (Q2 2026)
- Top 10 holdings = 79.5% of reported value
- Largest position: UTHR (UNITED THERAPEUTICS CORP DEL) at 13.5%
- Average position size: $428.32M
Sector Tilt
- Health Care 99.7%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 2 new, 12 added, 3 reduced, 6 exited
- 9 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.11M | $1.02B | 15.06% | Add | |
| 2 |
|
1.83M | $840.72M | 12.46% | Reduce | |
| 3 |
|
990.00K | $730.18M | 10.83% | Reduce | |
| 4 |
|
2.78M | $490.36M | 7.27% | Add | |
| 5 |
|
10.90M | $375.94M | 5.57% | Add | |
| 6 |
|
6.35M | $359.41M | 5.33% | Reduce | |
| 7 |
|
3.54M | $333.53M | 4.95% | Add | |
| 8 |
|
7.64M | $333.09M | 4.94% | Add | |
| 9 |
|
12.22M | $276.59M | 4.10% | Hold | |
| 10 |
|
10.81M | $262.10M | 3.89% | Add | |
| 11 |
|
4.44M | $259.42M | 3.85% | Add | |
| 12 |
|
5.40M | $216.81M | 3.21% | Hold | |
| 13 |
|
3.96M | $187.81M | 2.79% | Add | |
| 14 |
|
6.21M | $180.46M | 2.68% | Reduce | |
| 15 |
|
2.58M | $174.26M | 2.58% | Add | |
| 16 |
|
2.56M | $122.23M | 1.81% | Hold | |
| 17 |
|
10.25M | $119.82M | 1.78% | Add | |
| 18 |
|
15.03M | $118.40M | 1.75% | Reduce | |
| 19 |
|
6.39M | $93.90M | 1.39% | Reduce | |
| 20 |
|
21.70M | $70.96M | 1.05% | Hold | |
| 21 |
|
2.24M | $67.20M | 1.00% | Reduce | |
| 22 |
|
1.33M | $25.64M | 0.38% | New | |
| 23 |
|
1.34M | $25.16M | 0.37% | Add | |
| 24 |
|
4.47M | $24.00M | 0.36% | Reduce | |
| 25 |
|
2.00M | $14.34M | 0.21% | Reduce | |
| 26 |
|
1.25M | $9.49M | 0.14% | Reduce | |
| 27 |
|
2.85M | $5.41M | 0.08% | Hold | |
| 28 |
|
545.00K | $4.58M | 0.07% | New | |
| 29 |
|
200.00K | $4.44M | 0.07% | Reduce | |
| 30 |
|
250.00K | $2.24M | 0.03% | New | |
FAQ
What did Avoro Capital Advisors LLC buy in 2025-Q3?
In its 2025-Q3 13F filing, Avoro Capital Advisors LLC reported 30 equity positions worth $6.74B in aggregate; its largest disclosed positions were ASND ($1.02B), MDGL ($840.72M), ARGX ($730.18M).
How large is Avoro Capital Advisors LLC's portfolio?
Avoro Capital Advisors LLC reported $6.74B of long equity holdings across 30 positions as of 2025-Q3. Top-10 holdings account for 74.4% of reported value.
What is Avoro Capital Advisors LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.